ARCTICZYMES TECHNOLOGIES ASA Onderneming ArcticZymes Technologies ASA
Aandelen
AZT
NO0010014632
Biotechnologie & Medisch Onderzoek
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 25,7 NOK | -0,58% |
|
-1,15% | -38,81% |
Vakgebied
Verkoop per activiteit
| NOK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Enzymes
100,0
%
| 137 | 100,0 % | 119 | 100,0 % | -13,16% |
Verkoop per regio
| NOK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
United States
44,7
%
| 60 | 44,1 % | 53 | 44,7 % | -11,94% |
Lithuania
29,0
%
| 28 | 20,5 % | 35 | 29,0 % | +23,15% |
Other Countries in Europe
11,0
%
| 18 | 13,0 % | 13 | 11,0 % | -26,47% |
Germany
6,0
%
| 12 | 8,8 % | 7 | 6,0 % | -40,48% |
Rest of World
3,8
%
| 16 | 11,5 % | 5 | 3,8 % | -71,34% |
France
2,9
%
| - | - | 3 | 2,9 % | - |
Italy
2,4
%
| 3 | 1,9 % | 3 | 2,4 % | +9,83% |
Norway
0,2
%
| 0 | 0,3 % | 0 | 0,2 % | -48,86% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
Michael Akoh
CEO | Chief Executive Officer | - | 18-09-23 |
Børge Sørvoll
DFI | Director of Finance/CFO | 49 | 01-10-14 |
Darren Ellis
CTO | Chief Tech/Sci/R&D Officer | - | 01-12-22 |
| Chief Operating Officer | 56 | - | |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-01-00 |
Dirk Hahneiser
SAM | Sales & Marketing | 56 | 01-01-22 |
Dino DiCamillo
SAM | Sales & Marketing | 66 | 01-01-12 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
Marie Roskrow
CHM | Chairman | - | - |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01-01-00 |
| Chief Operating Officer | 56 | - | |
Jane Theaker
BRD | Director/Board Member | - | - |
Bernd Striberny
BRD | Director/Board Member | - | - |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 50 871 390 | 35 904 791 ( 70,58 %) | 0 | 70,58 % |
Bedrijfsgegevens
ArcticZymes Technologies ASA
Siva Innovasjonssenter Sykehusveien 23
9019, Tromsø
+47 77 64 89 00
http://www.arcticzymes.com
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The private company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. |
Medical Specialties
|
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. |
Pharmaceuticals: Major
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| -38,81% | 121 mln. | |
| +25,69% | 47,9 mld. | |
| +46,90% | 41,42 mld. | |
| -3,46% | 40,7 mld. | |
| -6,20% | 28,92 mld. | |
| +9,17% | 25,55 mld. | |
| -20,42% | 19,27 mld. | |
| +0,17% | 12,15 mld. | |
| +28,07% | 12,14 mld. | |
| -1,24% | 11,99 mld. |
